Skip to main content
Top
Published in: PharmacoEconomics 4/2018

01-04-2018 | Systematic Review

Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review

Authors: Dolly Han, Nicolas Iragorri, Fiona Clement, Diane Lorenzetti, Eldon Spackman

Published in: PharmacoEconomics | Issue 4/2018

Login to get access

Abstract

Background

Chronic constipation (CC) has a significant impact on patients’ quality of life and imposes an economic burden on individuals and the healthcare system. Treatment options include dietary changes, lifestyle modifications, fibre supplements, stool softeners, and laxatives.

Objective

We undertook this systematic review to comprehensively evaluate the cost effectiveness of treatments for CC.

Methods

We searched ten common databases to identify economic evaluations published to 13 June 2017. Abstract and full-text review were completed in duplicate. The quality of the included studies was assessed using the Consensus on Health Economic Criteria. Data extracted included costs and outcomes of treatments for CC and cost-effectiveness methods. A narrative synthesis was completed.

Results

From the 4338 unique citations identified, 79 proceeded to full-text review, with 10 studies forming the final dataset. Eight different definitions of CC were used to define the study populations. Study designs used were decision-tree models (4), Markov model (1), and retrospective (1) and prospective (4) studies. Quality-adjusted life-years (QALY) were reported in five studies; other outcomes included, discontinuation of laxative treatment and frequency of bowel movements. The majority of studies stated that their results were from a payer perspective; however, some of these studies only considered treatment costs, a subset of costs included in the payer perspective. Lifestyle advice, dietary treatments and abdominal massage were each compared with current care with laxatives, while polyethylene glycol (PEG) and senna–fibre combination were each compared with lactulose. Two studies compared newer treatments in patients who had not responded to laxatives: prucalopride was compared with continuing laxatives, and linaclotide was compared with lubiprostone. All of the interventions were reported by the study authors to be cost effective, with the exception of abdominal massage.

Conclusions

A consistent definition of CC is needed and the QALY should be used to capture the diverse symptoms of CC. Further analysis is needed comparing all available treatments for patients who have not responded to laxatives. Overall, results from economic evaluations appear to align with stepwise practice guidelines.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lindberg G, Hamid S, Malfertheiner P, Thomsen O, Fernandez L, Garisch J, et al. World gastroenterology organisation global guideline. J Clin Gastroenterol. 2011;45:483–7.CrossRef Lindberg G, Hamid S, Malfertheiner P, Thomsen O, Fernandez L, Garisch J, et al. World gastroenterology organisation global guideline. J Clin Gastroenterol. 2011;45:483–7.CrossRef
2.
go back to reference Crowell MD, Harris LA, Lunsford TNDJ. Emerging drugs for chronic constipation. Expert Opin Emerg Drugs. 2009;14:493–504.CrossRef Crowell MD, Harris LA, Lunsford TNDJ. Emerging drugs for chronic constipation. Expert Opin Emerg Drugs. 2009;14:493–504.CrossRef
3.
go back to reference Gonzalez-Martinez MA, Ortiz-Olvera NX, Mendez-Navarro J. Novel pharmacological therapies for management of chronic constipation. J Clin Gastroenterol. 2014;48:21–8.CrossRef Gonzalez-Martinez MA, Ortiz-Olvera NX, Mendez-Navarro J. Novel pharmacological therapies for management of chronic constipation. J Clin Gastroenterol. 2014;48:21–8.CrossRef
4.
go back to reference Faigel DO. A clinical approach to constipation. Clin Cornerstone. 2002;4:11–21.CrossRef Faigel DO. A clinical approach to constipation. Clin Cornerstone. 2002;4:11–21.CrossRef
5.
go back to reference Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005;23:461–76.CrossRef Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005;23:461–76.CrossRef
6.
go back to reference Dik VK, Siersema PD, Joseph A, Hodgkins P, Smeets HM, van Oijen MGH. Constipation-related direct medical costs in 16,887 patients newly diagnosed with chronic constipation. Eur J Gastroenterol Hepatol. 2014;26:1260–6.CrossRef Dik VK, Siersema PD, Joseph A, Hodgkins P, Smeets HM, van Oijen MGH. Constipation-related direct medical costs in 16,887 patients newly diagnosed with chronic constipation. Eur J Gastroenterol Hepatol. 2014;26:1260–6.CrossRef
7.
go back to reference Johanson JF. Review of the treatment options for chronic constipation. Med Gen Med. 2007;9:25. Johanson JF. Review of the treatment options for chronic constipation. Med Gen Med. 2007;9:25.
8.
go back to reference Bharucha AE, Dorn SD, Lembo A, Pressman A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144:211–7.CrossRef Bharucha AE, Dorn SD, Lembo A, Pressman A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144:211–7.CrossRef
9.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRef
10.
go back to reference Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21:240–5.PubMed Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21:240–5.PubMed
11.
go back to reference Taylor RR, Guest JF. Clinical trial: cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK. Aliment Pharmacol Ther. 2009;31:302–12.PubMed Taylor RR, Guest JF. Clinical trial: cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK. Aliment Pharmacol Ther. 2009;31:302–12.PubMed
12.
go back to reference Nuijten MJC, Dubois DJ, Joseph A, Annemans L. Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands. Front Pharmacol. 2015;6:67.CrossRef Nuijten MJC, Dubois DJ, Joseph A, Annemans L. Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands. Front Pharmacol. 2015;6:67.CrossRef
13.
go back to reference Passmore AP, Wilson-Davies K, Stoker C, Scott ME. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fibre combination. BMJ. 1993;307:769–71.CrossRef Passmore AP, Wilson-Davies K, Stoker C, Scott ME. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fibre combination. BMJ. 1993;307:769–71.CrossRef
14.
go back to reference Speed C, Heaven B, Adamson A, Bond J, Corbett S, Lake A, et al. LIFELAX—diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial. Health Technol Assess (Rockv). 2010;14:1–251. Speed C, Heaven B, Adamson A, Bond J, Corbett S, Lake A, et al. LIFELAX—diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial. Health Technol Assess (Rockv). 2010;14:1–251.
15.
go back to reference Huang H, Taylor DCA, Carson RT, Sarocco P, Friedman M, Munsell M, et al. Economic evaluation of linaclotide for the treatment of adult patients with chronic idiopathic constipation in the United States. Manag Care. 2016;25:41–8.PubMed Huang H, Taylor DCA, Carson RT, Sarocco P, Friedman M, Munsell M, et al. Economic evaluation of linaclotide for the treatment of adult patients with chronic idiopathic constipation in the United States. Manag Care. 2016;25:41–8.PubMed
16.
go back to reference Guest JF, Clegg JP, Helter MT. Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK. Curr Med Res Opin. 2008;24:1841–52.CrossRef Guest JF, Clegg JP, Helter MT. Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK. Curr Med Res Opin. 2008;24:1841–52.CrossRef
17.
go back to reference Christie AH, Culbert P, Guest JF. Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK. Pharmacoeconomics. 2002;20:49–60.CrossRef Christie AH, Culbert P, Guest JF. Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK. Pharmacoeconomics. 2002;20:49–60.CrossRef
18.
go back to reference Bub S, Brinckmann J, Cicconetti G, Valentine B. Efficacy of an herbal dietary supplement (Smooth Move) in the management of constipation in nursing home residents: a randomized, double-blind, placebo-controlled study. J Am Med Dir Assoc. 2006;7:556–61.CrossRef Bub S, Brinckmann J, Cicconetti G, Valentine B. Efficacy of an herbal dietary supplement (Smooth Move) in the management of constipation in nursing home residents: a randomized, double-blind, placebo-controlled study. J Am Med Dir Assoc. 2006;7:556–61.CrossRef
19.
go back to reference Lämås K, Lindholm L, Engström B, Jacobsson C. Abdominal massage for people with constipation: a cost utility analysis. J Adv Nurs. 2010;66:1719–29.CrossRef Lämås K, Lindholm L, Engström B, Jacobsson C. Abdominal massage for people with constipation: a cost utility analysis. J Adv Nurs. 2010;66:1719–29.CrossRef
20.
go back to reference Migeon-Duballet I, Chabin M, Gautier A, Mistouflet T, Bonnet M, Aubert JM, et al. Long-term efficacy and cost-effectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population. Curr Med Res Opin. 2006;22:1227–35.CrossRef Migeon-Duballet I, Chabin M, Gautier A, Mistouflet T, Bonnet M, Aubert JM, et al. Long-term efficacy and cost-effectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population. Curr Med Res Opin. 2006;22:1227–35.CrossRef
21.
go back to reference Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl 2):II43–7.PubMed Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl 2):II43–7.PubMed
22.
go back to reference National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 | Guidance and guidelines. London: National Institute for Health and Care Excellence; 2013. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 | Guidance and guidelines. London: National Institute for Health and Care Excellence; 2013.
23.
go back to reference Drummond M, Sculpher M, Claxton K, Stoddard G, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015. Drummond M, Sculpher M, Claxton K, Stoddard G, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
24.
go back to reference Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses. JAMA. 2016;316:1093.CrossRef Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses. JAMA. 2016;316:1093.CrossRef
26.
go back to reference Fleurence RL, Spackman DE, Hollenbeak C. Does the funding source influence the results in economic evaluations? Pharmacoeconomics. 2010;28:295–306.CrossRef Fleurence RL, Spackman DE, Hollenbeak C. Does the funding source influence the results in economic evaluations? Pharmacoeconomics. 2010;28:295–306.CrossRef
27.
go back to reference Asaria M, Griffin S, Cookson R. Distributional cost-effectiveness analysis. Med Decis Mak. 2016;36:8–19.CrossRef Asaria M, Griffin S, Cookson R. Distributional cost-effectiveness analysis. Med Decis Mak. 2016;36:8–19.CrossRef
Metadata
Title
Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review
Authors
Dolly Han
Nicolas Iragorri
Fiona Clement
Diane Lorenzetti
Eldon Spackman
Publication date
01-04-2018
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 4/2018
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-018-0609-6

Other articles of this Issue 4/2018

PharmacoEconomics 4/2018 Go to the issue